India’s Maypharm secures exclusive LATAM rights for Mediogen’s probiotic weight loss strain < Pharma < Article

Korean probiotic research and manufacturing firm Mediogen said it has signed an exclusive distribution agreement with India-based Maypharm Life Sciences for its proprietary weight loss probiotic strain MED-02, targeting the Mexican and Brazilian markets.

Mediogen partners with India’s Maypharm to launch weight loss probiotic MED-02 in Mexico and Brazil, marking its official entry into the Latin American market through a exclusive distribution deal.

Under the five-year strategic partnership, Maypharm Life Sciences has secured exclusive rights to distribute and sell MED-02 in both Mexico and Brazil, with a guaranteed order volume worth 5 billion won ($3.4 million) over the contract period. This marks Mediogen’s official entry into the high-potential Latin American market.

Maypharm Life Sciences operates subsidiaries in São Paulo and Mexico, establishing a strong regional footprint across Latin America. Through this agreement, the company will manage the local distribution and marketing of MED-02 in the two key markets.

MED-02 (Limosilactobacillus fermentum mixture MG4231 & MG4244) is a highly functional probiotic formulation developed by Mediogen. Designed to aid body fat reduction and support gut health, the strain has been scientifically validated through multiple clinical studies for both its efficacy and safety.

“This partnership allows us to accelerate our global expansion following recent success in Southeast Asia,” Mediogen Chief Strategy Officer Brian Kim said. “We will continue to leverage our leading R&D capabilities and largest probiotic production facilities in Korea to expand exports of functional probiotics in areas such as weight control, women’s health, digestive wellness, oral care, and skin health.”

Founded in 2000, Mediogen specializes in probiotic development and manufacturing. In 2020, the company attracted investment from Yuhan Corp. and GI Innovation, with Yuhan now holding the largest stake.

GI Innovation CEO Hong Jun-ho  serves as CEO of Mediogen. The company is also a key producer of Yuhan’s WiseBiome probiotic series and GI Biome’s Number 7 formulation.

_{Images are for reference only.Images and contents gathered automatic from google or 3rd party sources.All rights on the images and contents are with their legal original owners.}